Friedreich's ataxia (FRDA) is an autosomal recessive disease caused by mutations that produce a deficiency in frataxin. Despite the importance of neurodegeneration in FRDA, little is known about the consequences of frataxin deficiency in neuronal cells. Here we describe a neuronal cell model for FRDA based on the use of lentiviral vectors that carry minigenes encoding frataxin-specific shRNAs that silence the expression of this gene. These lentivectors can knockdown frataxin expression in human neuroblastoma SH-SY5Y cells, which results in large-scale cell death in differentiated neuron-like cells but not in undifferentiated neuroblastoma cells. Frataxin-deficient neuron-like cells appear to die through apoptosis that is accompanied by up-regulation of p53, PUMA and Bax and activation of caspase-3. No significant autophagy is observed in frataxin-deficient neuron-like cells and the pharmacological activation of autophagy does not significantly increase neuronal cell death in response to the frataxin deficiency. Cell death triggered by frataxin knockdown can be impaired by interference with p53, caspase inhibitors and gene transfer of FXN. These results suggest that frataxin gene silencing in human neuron-like cells may constitute a useful cell model to characterize the molecular changes triggered by frataxin deficiency in neurons, as well as to search for therapies that may protect against neurodegeneration.
INTRODUCTION
Friedreich's ataxia (FRDA) is the most common hereditary ataxia in Caucasians and it is a predominantly neurodegenerative disease. Typically, the neurodegeneration that occurs in FRDA preferentially affects certain types of neurons in the spinal ganglia (dorsal root ganglia), spinal cord (mainly the spinocerebellar tract and posterior columns), brainstem and cerebellum (cerebellar dentate nuclei). Clinically, FRDA patients suffer progressive limb and gait ataxia, the onset of which usually occurs early, around the start of puberty. The most important extraneurological manifestations of FRDA are hypertrophic cardiomyopathy and diabetes mellitus (1, 2) .
From a genetic viewpoint, FRDA is an autosomal recessive disease caused by mutations in the FXN (frataxin) gene (mapped to chromosome 9q13), which codes for a mitochondrial protein known as frataxin (3) . The mutation chiefly responsible for this disease is the expansion of a GAA trinucleotide repeat located in the gene's first intron, which leads to a reduction in frataxin expression due to the inhibition of transcription associated with 'heterochromatinization' of the locus. Both the age at which the disease appears and its severity is inversely correlated with the length of the GAA triplet expansion. Therefore, frataxin deficiency appears to be responsible for the degenerative processes that characterize this disease (1, 4) . The majority of FRDA patients have the frataxin levels of 10% the normal values. However, those patients with later onset and less severe forms of the disease have frataxin levels of 25% normal values. Heterozygotic carriers accumulate 50% of the normal values of frataxin and show no clinical signs of the disease (4) .
Frataxin is a ubiquitous protein expressed in all cell types and it has been highly conserved during evolution, from Gramnegative bacteria to mammals (5) . In mammalian cells, frataxin is synthesized as a precursor polypeptide and it is then directed to the mitochondria where it is proteolytically cleaved to the mature and functional forms of the protein (6, 7) .
Although there is still some debate about the exact functions performed by frataxin, it is widely accepted that it is involved in mitochondrial iron homeostasis, the biosynthesis of iron -sulphur complexes and the heme group, stimulation of oxidative phosphorylation and the regulation of oxidative stress. Accordingly, it has been proposed that FRDA may result from disturbances in the utilization of mitochondrial iron, as well as from modifications in the activity and biogenesis of various frataxin-interacting mitochondrial proteins (8, 9) . Different experimental models have been used to better understand the biological role of frataxin and the pathogenic mechanisms involved in FRDA. In this regard, mammalian cell models are of particular interest, since they are useful for the study of the molecular pathophysiology of the disease and for the high throughput screening of potential therapeutic drugs. Widely used mammalian cell models of frataxin deficiency include primary fibroblast cultures (10) (11) (12) and peripheral blood cells from FRDA patients (13) , as well as established cell lines in which frataxin levels are reduced by antisense gene expression (14) or RNA interference (15) (16) (17) (18) . Curiously, few cell models of frataxin deficiency involving neural cells have been used, despite the fact that FRDA is essentially a neurodegenerative disease.
Here, we describe a neuronal cell model for frataxin deficiency involving the transduction of human neuroblastoma SH-SY5Y cells with lentiviral vectors carrying minigenes for frataxin RNA interference. This neuroblastoma cell line is a 'neuroblastic' clone of the 'mixed' human neuroblastoma line SK-N-SH (19) , and it has been extensively used to study neuronal function, differentiation and degeneration. 'Neuroblastic' SH-SY5Y cells are capable of unlimited proliferation in vitro and exhibit a phenotype which is close to that of embryonic neuroblasts. Interestingly, SH-SY5Y cells retain the ability to stop proliferating and to differentiate into post-mitotic cells with many features of mature neurons upon treatment with various agents (20) (21) (22) . This ability of SH-SY5Y cells to proliferate, as well as to differentiate into human neuron-like cells, makes it an excellent in vitro system to study the effects of frataxin deficiency.
Using SH-SY5Y cells as a model system, we found that frataxin deficiency only moderately affects the viability and capacity for neuronal differentiation of neuroblastoma cells (although it significantly inhibits their proliferation), while depletion of frataxin induces large-scale apoptosis in differentiated neuron-like cells. These results are consistent with the view that activation of apoptosis in frataxin-deficient mature neurons may contribute to neurodegeneration in FRDA.
RESULTS

Frataxin silencing augments cell death and decreases proliferation in human neuroblastoma SH-SY5Y cells
Silencing of frataxin in human neuroblastoma SH-SY5Y cells (growing as proliferating cells under standard culture conditions) was achieved through transduction with lentiviral vectors encoding two different short-hairpin RNA sequences against human frataxin (shRNA 37 and shRNA 38). The transduction of shRNA 37 decreased the availability of the frataxin protein to 11% of the level found in control cells 96 h posttransduction, as evident in western blots (Fig. 1A) . Similarly, the residual levels of frataxin in SH-SY5Y cells transduced with shRNA 38 were 30%. In contrast, no changes in frataxin expression were seen in cells treated with a scrambled or random interference sequence (shRNA sc), or in untransduced cells. Interestingly, the level of reactive oxygen species (ROS) as measured using the fluorescent probe Mito-SOX TM Red at 48 h post-transduction was modestly, but significantly, increased in frataxin-deficient cells when compared with cells transduced with the shRNA sc (Fig. 1B) . Furthermore, the dramatic decrease in frataxin elicited by shRNA 37 was accompanied by a small but significant increase in cell death (up to 20% when compared with the controls), although no significant differences were observed when the cells were treated with shRNA 38 (Fig. 1C) .
To characterize the increase in cell death occurring in proliferating SH-SY5Y cells in response to frataxin deficiency, caspase-3 activation that is a marker of apoptosis (23) , was analysed using western blots (Fig. 1D) . We found strong caspase-3 activation that paralleled both the increased cell death and the decrease in frataxin level in shRNA 37-transduced cells.
Frataxin-deficient neuroblastoma cells transduced with shRNA 37 did not exhibit significant morphological differences when compared with control cells. However, the loss of frataxin was accompanied by a marked decrease in proliferation that was evident 96 h post-transduction as measured by 5-bromo-2 ′ -deoxyuridine (BrdU) incorporation (Fig. 1E) . Thus, the number of BrdU-labelled proliferating cells was reduced to a 50% when comparing frataxin-deficient with control cells. No significant differences were seen between shRNA 38-or shRNA sc-transduced cells, suggesting that silencing frataxin expression below a specific threshold may be necessary to arrest cell proliferation and trigger cell death in proliferating undifferentiated SH-SY5Y cells.
Silencing of frataxin does not affect the neuronal differentiation of human SH-SY5Y cells, although it increases their susceptibility to stress
To test whether or not frataxin deficiency affects the ability of neuroblastoma cells to differentiate into neuron-like cells, SH-SY5Y cells were transduced with shRNA 37 and shRNA sc lentivectors before subjecting them to the protocol of neuronal differentiation. Frataxin-deficient cells were able to differentiate into neuron-like cells ( Fig. 2A) , although an increase in their cell death was observed. Immunocytochemical analysis demonstrated that the frataxin-deficient neuronlike cells expressed microtubule-associated protein (MAP) 2A/B within cell bodies and dendrites in a similar way to differentiated control cells (Fig. 2B) . No prominent effect of frataxin-deficiency was evident on the number, length and morphology of neurites (data not shown). However, terminally differentiated neuron-like cells lacking frataxin appeared to be more susceptible to stress. There was an increase of 10% in the number of dead cells when frataxin was silenced by shRNA 37 transduction (compared with the shRNA sc-transduced cells), after 10 days of differentiation (Fig. 2C ). This increase in cell death augmented and reached 24% simply after replacing the culture medium with a fresh medium, which is known to cause some cell stress (Fig. 2C ). These findings suggest that frataxin may not be essential for the neuronal differentiation of human neuroblastoma SH-SY5Y cells although it may play a crucial role in the viability of differentiated neurons.
Frataxin knockdown triggers cell death in human neuron-like cells
To test for the effect of frataxin silencing in neuron-like cells, neuroblastoma SH-SY5Y cells were previously differentiated into mature neuron-like cells and then transduced with lentiviral-derived particles encoding shRNA 37, shRNA 38 or shRNA sc. Frataxin levels were measured using western blots 96 h post-transduction (Fig. 3A) . Transduction with shRNA 37 produced a noteworthy decrease in frataxin gene expression to almost 8% of the control values. In neurons transduced with shRNA 38 the levels of frataxin were 17% of the controls, whereas there was no significant difference in frataxin expression between the shRNA sc-transduced and untransduced control neurons. The level of ROS measured using the fluorescent probe MitoSOX TM Red was significantly increased in frataxindeficient neuron-like cells at 48 h post-transduction, when compared with neuron-like cells transduced with shRNA sc (Fig. 3B) . Interestingly, the increase in the level of ROS triggered by frataxin deficiency was higher in differentiated neuron-like cells than in undifferentiated neuroblastoma cells (compare Fig. 3B with Fig. 1B ). MitoSOX TM Red is a probe which is particularly sensitive to mitochondrial superoxide anion, so these results suggest that the knockdown of frataxin provokes a more significant mitochondrial dysfunction in differentiated neuron-like cells.
Frataxin knockdown in human neuron-like cells was accompanied by an increase in cell death 96 h posttransduction (Fig. 3C) , as measured by the calcein/propidium iodide incorporation assay. Indeed, more than half of the population of the cells transduced with shRNA 37 and more than 30% of the neurons transduced with shRNA 38 died within 96 h, when compared with the shRNA sc control. A detailed time course of frataxin silencing was obtained over 96 h posttransduction (Fig. 3D) . A significant decrease in frataxin was detected as soon as 24 h post-transduction with both vectors shRNA 37 and shRNA 38, and reached the lowest level at 72 h post-transduction, which was maintained at least up to 96 h post-transduction (Fig. 3E) . Similarly, when neuronal viability was assayed in parallel, there was an increase in the number of dead cells in the cultures transduced with either shRNA 37 or shRNA 38, even at 24 h post-transduction (Fig. 3F) . Thus, it appears that neuron-like cells are more susceptible than undifferentiated neuroblastoma cells to an acute silencing of frataxin gene expression.
Cell death of frataxin-deficient neuron-like cells is apoptotic
To gain further insight into the molecular mechanisms underlying the demise of neuron-like cells devoid of frataxin, caspase-3 activation was examined (Fig. 4A) . As in the undifferentiated cells, strong and robust activation of caspase-3 was detected in neuron-like cells transduced with shRNA 37. This activation first appeared at 24 h, it reached a maximum after 48 h and it was maintained for up to 96 h. Caspase-3 activation in neurons transduced with shRNA 38 was also observed, albeit to a lesser extent. In control cells, a certain level of caspase-3 activation was also found at 96 h, possibly due to nutrient deprivation of the culture medium.
The role of caspase activation in neuronal cell death triggered by frataxin deficiency was tested using different protease inhibitors. Accordingly, differentiated SH-SY5Y cells were transduced with the lentiviral-derived particles and 6 h later the culture medium was replaced by fresh medium containing different protease inhibitors. The viability of the cells was assayed 48 h post-transduction (Fig. 4B) when the activation of caspase-3 was at its peak. Neuronal cell death was significantly reduced in the presence of the pan-caspase inhibitors, z-VAD-fmk and Q-VD-OPh. Treatment with z-VAD-fmk (100 mM) diminished the number of dead frataxin-deficient neurons to 10% and treatment with Q-VD-OPh (50 mM) almost completely reversed the cell death observed in frataxindeficient neurons. When other protease inhibitors were used, cathepsin inhibitors (Z-FA-fmk 5 mM and pepstatin A 50 mM) had no effect, while a broad-spectrum calpain inhibitor, calpeptin (10 mM), efficiently decreased the number of dead cells in neuron-like cells transduced with shRNA 37. The protective effect of calpeptin was transient since it was evident at 48 h but not at longer time points (see also Fig. 8B ).
In view of the involvement of caspase-3 and possibly also of calpain, the appearance of specific a-fodrin (a-II-spectrin) breakdown products was examined since this protein is very susceptible to proteolysis in neurons (24) . The a-fodrin peptide resulting from calpain cleavage has a molecular weight of 145-150 kDa, while the product corresponding to caspase cleavage has a molecular weight close to 120 kDa. Figure 4C shows an increase in calpain and caspasemediated proteolysis of a-fodrin in frataxin-deficient neuronlike cells. The a-fodrin cleavage products caused by calpain and caspase activation in frataxin-deficient neurons diminished after the addition of specific protease inhibitors ( Fig. 4D ), indicating that both caspases and calpains are indeed activated in frataxin-deficient neuron-like cells.
The nuclear morphology of frataxin-deficient neuron-like cells was assessed by immunofluorescence using 4 ′ -6-diamidine-2-phenylindole (DAPI) staining. Nuclear condensation and fragmentation are major hallmarks of apoptotic cell death, and we found an increase in the number of condensed and fragmented nuclei in the frataxin-deficient neurons 96 h post-transduction. This phenotype was completely prevented by the pan-caspase inhibitor, Q-VD-OPh (50 mM), with the nuclei appearing larger and swollen after such treatment (Fig. 5A ). The terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay also detects an extensive nuclear DNA fragmentation and there was an increase in the number of TUNEL-labelled neurons in the frataxin-deficient cells at 96 h post-transduction (Fig. 5B ). About 40% of nuclei from neuron-like cells transduced with shRNA 37 were TUNEL-positive, whereas 24% of nuclei from neuron-like cells transduced with shRNA 38 were TUNEL-positive. Exposure to the pan-caspase inhibitor Q-VD-OPh (50 mM) notably reduced the number of TUNELpositive nuclei in neurons transduced with shRNA 37 and shRNA 38. Together, these results indicate that neuron-like cells devoid of frataxin die through apoptosis.
p53 is a key mediator in the apoptotic cell death of frataxin-deficient neuron-like cells
The transcription factor p53 has been described to play a key role in the induction of neuronal apoptosis in response to diverse insults, including oxidative stress and DNA damage (25) . Accordingly, the level of p53, together with the levels of two of its transcriptional targets, PUMA and Bax, was analysed in differentiated SH-SY5Y cells 48 h after transduction with the lentiviral vectors encoding for shRNAs. Figure 6A shows a significant increase in the levels of p53, PUMA and Bax in frataxin-deficient neuron-like cells which are correlated with the activation of caspase-3.
To determine the functional relevance of p53 induction in frataxin-deficient neuron-like cells, lentiviral vectors bearing two shRNA sequences against p53 (shRNA p53-53 and shRNA p53-55) were used to knockdown p53 expression. Thus, differentiated SH-SY5Y cells were co-transduced with lentiviral vectors carrying shRNA sequences against frataxin and p53. Figure 6A shows that a significant decrease in the levels of p53, PUMA and Bax can be observed in frataxindeficient cells transduced with either shRNA p53-53 or shRNA p53-55 (although this effect was more evident in cells transduced with shRNA p53-55). Interestingly, the knockdown of p53 and its transcriptional targets is well correlated with a diminished activation of caspase-3. Figure 6B shows a significant reduction in the levels of active caspase-3 after transduction of frataxin-deficient neuron-like cells with shRNA p53-55. * P ≤ 0.05, * * P ≤ 0.01. (C) Western blot analysis of a-fodrin cleavage products at 48 h post-transduction with shRNA 37, either in the absence or in the presence of 10 mM calpeptin and/or 50 mM Q-VD-OPh. Shown are the major calpain-cleaved and caspase-cleaved protein fragments from a-fodrin. (D) Quantification of calpain and caspase-cleaved a-fodrin products at 48 h post-transduction with shRNA 37, either in the absence or in the presence of 10 mM calpeptin and/or 50 mM Q-VD-OPh.
* P ≤ 0.05, * * P ≤ 0.01.
Cell viability was also determined to test for the effect of p53 knockdown. Figure 6C shows that knockdown of p53 indeed resulted in significantly lower rates of death of frataxindeficient neuron-like cells. These results suggest the involvement of p53 in the apoptotic pathway triggered by frataxin deficiency in neuronal cells.
Cell death of frataxin-deficient cells is independent of autophagy
A large number of autophagic-like vacuoles have been observed in some neurons within the nervous system of mice with a conditional frataxin deficiency (26) . Accordingly, the occurrence of autophagy was examined in our cell models for frataxin deficiency. Silencing of frataxin in undifferentiated neuroblastoma SH-SY5Y cells results in a rate of cell death of 20% at 96 h post-transduction. As shown in Figure 7A and B, this cell death was not accompanied by any increase in the level of the lipidated form of microtubule-associated protein 1 light chain 3 (LC-3 II), which is a well-established marker for autophagy (27) . Hence, in this model, autophagy did not correlate with cell demise. Moreover, cell death was almost completely prevented by treating the cells with Q-VD-OPh, a pan-caspase inhibitor. To enhance autophagy, we treated our SH-SY5Y cells with the calpain inhibitor, calpeptin (28) . Figure 7A shows that calpeptin strongly activated autophagy, measured by the increase in LC-3 II, but this activation was not correlated with any significant change in cell survival (at 96 h posttransduction). The induction of autophagy was confirmed by acridine orange staining which measured the acidic content of the cells and is widely used as an indicator of autophagy and autophagolysosome content ( Fig. 7C and D) . Again, there was no significant increase in the acidic content in frataxin-deficient cells by itself, whereas there was a robust increase in the autophagolysosome content when exposed to the calpain inhibitor, calpeptin.
We have also tested for the implication of autophagy in the cellular demise induced by frataxin deficiency in differentiated SH-SY5Y cells (Fig. 8) . Again, no significant increase in LC-3 II was detected in frataxin-deficient neuron-like cells, while the cell death was close to 60% at 96 h post-transduction. When the human neuron-like cells were exposed to the calpain inhibitor, calpeptin, the rate of autophagy increased, as measured by the appearance of LC-3 II (Fig. 8A ), but no changes in cell death or caspase-3 activation were detected at 96 h post-transduction (Fig. 8B ). This indicates that the decrease in cell death which is observed after calpeptin treatment at 48 h post-transduction (see Fig. 4B ) is only temporary. Together, these data indicate that a strong activation of autophagy does not have a major long-lasting effect on the death of frataxin-deficient neuron-like cells.
FXN gene transfer inhibits cell death of frataxin-deficient neuron-like cells
As a proof of concept we have tested whether frataxin overexpression driven by lentiviral vector transduction can rescue the death of frataxin-deficient neuron-like cells. Hence, we first co-transduced differentiated SH-SY5Y cells with shRNA sequences and frataxin or enhanced green fluorescent protein (eGFP) overexpressing lentivectors. In this case, a multiplicity of infection (MOI) of 5 was used to transduce the cells with the shRNA sequences and a MOI of 3 was used to transduce them with the lentivectors overexpressing frataxin or eGFP. Using these MOIs, more than 90% of the cell culture was transduced with the shRNA sequences and on this background, 60% of the neuron-like cells expressed transgenic frataxin or eGFP. After 96 h post-transduction, we quantified the number of fragmented DAPI-stained nuclei by fluorescence microscopy (Fig. 9A) . As described above, frataxin-deficient cells presented fragmented nuclei, but this fragmentation was prevented by frataxin overexpression. Indeed, there was a decrease in the number of cells with fragmented nuclei close to 12% when compared with the frataxin-depleted neuron-like cells that expressed eGFP. The cells were also immunostained with an antibody against frataxin to confirm that the cells that overexpress the frataxin protein are those that had intact nuclei (Fig. 9B) . Previous studies have reported that the massive overexpression of eGFP may be toxic to neurons (29) and that the overexpression of frataxin may induce mild toxicity in cultured fibroblasts (30) . Our results support the view that enhanced frataxin expression may partially inhibit the neuronal cell death triggered by frataxin knockdown.
At a biochemical level, we have confirmed that the transduction of frataxin-deficient neuron-like cells with the lentivector encoding for frataxin results in an approximately normal level of frataxin as measured at 48 h post-transduction (Fig. 9C) . This normal level of frataxin is presumably attained because the expression of shRNA balances the overexpression of frataxin which is driven by the lentiviral vector. However, these determinations of frataxin levels correspond to the average values of the cell cultures, and we cannot rule out the existence of differences in frataxin expression among individual cells. In any case, these results demonstrate that the restoration of a close to normal level of frataxin upon lentiviral transduction of frataxin-deficient neuron-like cells produces a partial blockade of the apoptotic cell death.
DISCUSSION
FRDA is a predominantly (although not exclusively) neurodegenerative disease which is caused by a dramatic (but not total) frataxin deficiency. However, little is known about the molecular basis underlying the specific neurodegeneration occurring in FRDA (5, 9) . It is thought that frataxin is essential for cell viability. Indeed, inactivation of the FXN gene in mice produces early embryonic lethality. Therefore, the complete absence of frataxin may trigger a widespread cell death (31) . However, FRDA is not caused by the complete absence of frataxin and only affects particular cell types with certain neurons being the most dramatically affected. Furthermore, the presentation of the disease does not usually occur until around puberty. This suggests that normal development is permitted by the residual levels of frataxin in FRDA patients but that degeneration is then triggered in specific cell types (particularly in certain neurons). It is tempting to speculate that distinct thresholds for frataxin may underlie the differential effects on distinct cell types at specific stages of development, which could explain the correlation between frataxin levels and certain features of the disease. Accordingly, some neural cells (particularly neurons) might be more susceptible to frataxin deficiency, followed by other cell types such as cardiomyocytes and pancreatic beta cells. Thus, the development of 'neuronal' cell models of frataxin deficiency is crucial to understand the molecular mechanisms underlying neurodegeneration, as well as to test potential therapeutic approaches aimed at curbing the progressive neurological deterioration characteristic of FRDA patients. To generate neuronal cell models for frataxin deficiency, we have used lentivectors carrying minigenes that encode frataxin-specific shRNAs (shRNA 37 and shRNA 38). These vectors knockdown the expression of this gene, thereby reducing the frataxin levels to 8 -30% of the normal levels (depending on the vector used and the state of the cells), within the pathological range found in patients with FRDA. In human neuroblastoma SH-SY5Y cells, which are neuroblast-like cells with the ability to differentiate into neuron-like cells (20 -22) , frataxin silencing induces a massive death in differentiated neuron-like cells but not in undifferentiated cells. In the latter, a moderate increase in cell death and a significant inhibition of cell proliferation are only observed when the frataxin levels are reduced to 10% of normal levels by shRNA 37. Interestingly, shRNA 38 (which silences frataxin gene expression a little less efficiently than shRNA 37) fails to increase cell death in undifferentiated neuroblastoma cells, although it can trigger the death of differentiated neuron-like cells. Thus, shRNA 38 has a similar effect as shRNA 37 in differentiated neuron-like cells while it seems ineffective in undifferentiated neuroblastoma cells. The reasons for the discrepancies between the effects of shRNA 37 and shRNA 38 are not yet clear. We favour the view that there may be different thresholds of frataxin levels which produce specific biological outcomes in distinct cell types. Thus, the frataxin level which is attained after shRNA 38 transduction may be above the threshold value required to have a significant effect on undifferentiated neuroblastoma cells but below the threshold value required to activate the death of neuron-like cells. Our results with undifferentiated neuroblastoma cells transduced with shRNA 37 are similar to previous studies, showing that frataxin knockdown arrests cell proliferation of HeLa cells (18, 32) and murine fibroblasts (15) . Likewise, the death in undifferentiated neuroblast-like SH-SY5Y cells after frataxin gene silencing is also consistent with previous studies, demonstrating that frataxin deficiency renders a variety of established cell lines more susceptible to apoptosis (10, 12, (33) (34) (35) (36) . However, we found that no additional apoptotic insults are required to detect a low but significant rate of cell death in undifferentiated neuroblast-like SH-SY5Y cells after frataxin gene silencing. Possibly the 'neuroblastic' SH-SY5Y cell line is more susceptible to frataxin deficiency than other neural and non-neural cell lines. It is worth emphasizing that the susceptibility to apoptosis in response to frataxin deficiency is notably increased upon neuroblastoma cell differentiation. Thus, differentiated neuron-like cells die even when the silencing of frataxin is 30% (as in cells transduced with shRNA 38) Furthermore, there seems to be a correlation between the degree of frataxin silencing and the number of dying neuron-like cells.
Interestingly, frataxin deficiency has also been demonstrated to enhance apoptosis in embryonic stem-like cells differentiating into neuroectoderm (14) . In this case, stably-transfected clones of rat teratocarcinoma (embryonal carcinoma) P19 cells expressing an antisense construct of frataxin showed a much higher rate of apoptosis (compared with wild-type cells) after induction of neural differentiation with retinoic acid, resulting in a dramatic decrease in the number of neural progenitor and differentiated neuronal cells. It is well known that massive cell death normally accompanies neural differentiation of embryonic stem cells (37, 38) . Thus, frataxin deficiency may enhance the susceptibility of these differentiating embryonic stem-like cells to this cell death associated with neural differentiation. In contrast to P19 cells, we find that the neuronal differentiation of frataxin-deficient SH-SY5Y cells is practically normal, although the differentiated neuron-like cells are very susceptible to stress and die by apoptosis. These contrasting results may reflect the use of distinct experimental systems. Moreover, the differentiation of 'neuroblastic' SH-SY5Y cells into neuron-like cells is quite distinct from the neural differentiation of embryonal carcinoma cells, involving fewer steps and it is not normally accompanied by an increase in cell death. In any case, all these results support the view that frataxin-deficient neuronal cells are more susceptible to apoptotic cell death than non-neural cells. This again emphasizes that 'neuronal' cell models are essential to understand the pathophysiology of FRDA. Curiously, a recent study failed to detect any effect of frataxin knockdown on the viability and the proliferation of a variety of neural and non-neural cell lines (including neuroblastoma cells), while a significant decrease in proliferation was observed in different Schwann cell lines, a human oligodendroglial cell line and a human embryonal carcinoma cell line (16) . Moreover, cell death was only observed in some Schwann cell lines. It appears that distinct established cell lines differ in their susceptibility to frataxin gene silencing. This is not surprising since most established cell lines are derived from tumours with multiple gene alterations which may provoke, in some cases, an enhanced and uncontrolled proliferation, as well as an increased resistance to apoptosis. Thus, it is very important to choose adequate cell lines that may serve as useful cell models of frataxin deficiency. In this respect, the phenotype of the cells may be even more important than their lineage. Beyond its neural lineage, the 'neuroblastic' phenotype of SH-SY5Y cells and their ability to differentiate into mature neuron-like cells make this cell line a particularly relevant model to study the impact of frataxin deficiency on neurodegeneration (21, 22) .
The death of both undifferentiated and differentiated neuroblastoma SH-SY5Y cells has the morphological characteristics of apoptosis (including chromatin condensation and nuclear fragmentation). Indeed, it is accompanied by p53 induction and caspase-3 activation and it is inhibited by interference with p53 and caspase inhibitors (z-VAD-fmk, Q-VD-OPh). Thus, frataxin deficiency in our cellular model induces a rather typical apoptotic process. The importance of the transcription factor p53 in many cases of neuronal apoptosis is well established (25) . When neurons are subjected to oxidative stress and/or DNA damage, the transcription and posttranslational modifications of p53 are rapidly activated, leading to the induction of typical p53 target genes including the pro-apoptotic PUMA and Bax (39-42). Our results indicate that p53 is a crucial player in the apoptosis triggered by frataxin deficiency in neuron-like cells. Probably, p53 induction results from enhanced oxidative stress and DNA damage, which has been associated with the frataxin deficiency in a variety of cells (13, 43) . In view of these data, it is tempting to speculate that p53 is a key factor linking the mitochondrial dysfunction resulting from frataxin deficiency with the induction of pro-apoptotic factors such as PUMA and Bax, thus leading to apoptotic cell death in differentiated neurons. Interestingly, a genetic link between frataxin and p53 has also been reported in the nematode Caenorhabditis elegans, in which frataxin knockdown triggers a complex stress response which is regulated by p53/cep1 (44) . Moreover, a very recent report has demonstrated that frataxin deficiency induces p53 activation in normoxia while preventing it under hypoxia in a variety of cell lines (45) . Thus, a strong connection between frataxin deficiency and p53 activation in distinct cell types may be established.
In addition to caspases, calpain also appears to be activated in frataxin-deficient neuron-like cells. Calpain activation has been found in other neurodegenerative processes (46) and, in particular, both calpain and caspase-3 activation have recently been associated with mitochondrial dysfunction in a cell model of Parkinson's disease (47) . Furthermore, calpain is activated after calcium release from dysfunctional mitochondria under conditions of oxidative stress, also associated with oxidative damage to mitochondrial DNA (48) . Interestingly, a significant oxidative damage to both mitochondrial and nuclear DNA can be detected in peripheral blood cells from FRDA patients (13) . Accordingly, mitochondrial dysfunction and oxidative stress that may be caused by frataxin depletion (43) might trigger the induction of p53, PUMA and Bax which might subsequently lead to the activation of caspases and calpain, resulting in the apoptotic death of frataxin-deficient neuron-like cells.
Whereas frataxin deficiency in cultured neuron-like cells induces acute apoptotic cell death, it appears that neurodegeneration in vivo is a much slower and more chronic process, as observed in the various murine models of frataxin deficiency. The accumulation of a large number of vacuoles and of lipofuscin has been observed in some neurons in these models (26, 49) , leading to the proposal that frataxin deficiency could induce 'autophagic cell death' (26) . However, no specific markers were used to determine whether these vacuoles were indeed autophagosomes. Significantly, abundant lipid-containing vacuoles were recently demonstrated in a Drosophila model of FRDA that were not autophagosomes (50) . Furthermore, the concept of 'autophagic cell death' is controversial and the preferred term is 'cell death with autophagy' since autophagy is probably a survival response of cells subjected to stress (51, 52) . Under certain conditions, autophagy is not sufficient to protect cells and these die (53). Thus, it is possible that autophagy might be induced in vivo to protect frataxin-deficient neurons against stress, although degeneration is due to apoptosis. Curiously, apoptotic cells have been detected in FXN knock-out mouse embryos at embryonic days 6-7 (31), but not in a more restricted conditional knock-out mouse model (26) . Indeed, apoptosis is very difficult to detect in vivo because apoptotic neuronal cells are readily phagocytosed by neighbouring glial cells. Thus, apoptosis is usually only detected in vivo in the nervous system when it is very extensive (54) . So, even very careful examination may only reveal a few apoptotic cells in the course of a slow and chronic neurodegenerative process in which neurons finally die by apoptosis.
The fact that cultured neuron-like cells die by apoptosis after frataxin deficiency strongly suggests that this may be an important mechanism contributing to neurodegeneration in FRDA. Apoptosis has also been found to underlie cell death in Schwann cells after frataxin gene knockdown (16) and in pancreatic beta cells after tissue-specific FXN gene knock-out (55) . We found no evidence of significant autophagy in our acute models of frataxin deficiency in which cell death was also apoptotic. It is plausible that calpain activation in frataxin-deficient neuron-like cells may contribute to the inhibition of autophagy since calpain inhibition triggers autophagy (28, 52) . Thus, our results do not support an important role for autophagy in the degeneration of frataxindeficient neuron-like cells. Interestingly, calpain inhibition transiently decreases neuronal cell death after frataxin knockdown. This temporary increase in cell survival might be due to a protective effect of autophagy induction. However, this possible neuroprotective effect is not long-lasting since it cannot be detected at 96 h after frataxin knockdown. In any case, whether autophagy plays a role in frataxin deficiency in chronic animal models is still an open question. Thus, further studies are required to understand the potential role of the cross-talk between apoptosis and autophagy in neurodegeneration in FRDA.
In any case, neuronal cell death is the last stage in the course of neurodegeneration, and probably synaptic dysfunction is much more important at the early stages of the disease. It is plausible that the influence of neurotrophic factors and other cell interactions considerably delay neuronal cell death in vivo when compared with in vitro. This might explain why some neurodegenerative processes appear to be 'reversible' during some time in vivo. As a case in point, the viral vector-mediated knock-out of the FXN gene in the brainstem of transgenic (floxed) mice provoked a detectable behavioural deficit after 4 weeks, and this was reversible after subsequent FXN gene transfer (56) .
Curiously, some proteins associated with apoptosis such as p53 and caspase-3 may also perform crucial roles at the early stages of neurodegeneration. Thus, strong immunoreactivity for p53 has been correlated with a stress response and delayed death of Purkinje cells in a mouse model of Cockayne syndrome (57) . Likewise, localized activation of caspase-3 within synapses has been associated with synaptic depression (58) in the absence of neuronal cell death. It is thus tempting to speculate that p53 induction and subsequent caspase-3 activation may first lead to synaptic failure and only later result in apoptotic neuronal cell death.
In summary, the lentivector-mediated knockdown of frataxin gene expression in 'neuroblastic' SH-SY5Y cells, particularly in differentiated neuron-like cells, may constitute a useful 'neuronal' cell model for frataxin deficiency. Major advantages of this approach include the possibility of culturing human neuron-like cells of a clonal origin and the availability of a homogeneous population of cells for biochemical studies. Accordingly, this 'neuronal' cell model may be employed to study the molecular mechanisms underlying the degeneration of frataxin-deficient neuron-like cells, and to search for novel therapeutic targets and biomarkers of neurodegeneration in FRDA. It may also serve as a platform for the screening of molecules with neuroprotective properties. 
MATERIALS AND METHODS
Reagents
Cell culture
Human SH-SY5Y neuroblastoma cells were routinely grown in Dulbecco's modified eagle medium supplemented with 10% heat-inactivated FBS, containing 2 mM L-glutamine and penicillin/streptomycin (100 U/ml and 100 mg/ml, respectively), in a humidified incubator at 378C and 5% CO 2 . The cells were differentiated as described previously (21) . Briefly, 6 × 10 3 cells/cm 2 were seeded on Matrigel TM Basement Membrane Matrix-coated culture dishes and they were allowed to attach overnight. The FBS content of the culture medium was then reduced to 5% and the cells were exposed to 10 mM retinoic acid. The cells were kept under these conditions for 5 days, changing the culture medium every 2 days. Subsequently, the cells were cultured in a Neurobasal medium supplemented with B-27, 2 mM GlutaMax I, 2 mM dibutyryl-cyclic AMP, 20 mM potassium chloride (KCl), 50 ng/ml rhBDNF, penicillin/streptomycin and gentamicin 50 mg/ml, in which they were maintained for 5 days.
For drug treatments, the compounds were added to the culture medium and they were replaced every 48 h without changing the culture medium. As controls, cells were treated with the vehicle in which the drug was prepared.
Lentiviral production and titration
Lentiviral vectors encoding short-hairpin RNA sequences were purchased from Sigma and they contained either the sequences against human frataxin (Mission w shRNA, Gene Bank accession number NM_000144), hereafter referred to as shRNA 37 and shRNA 38, and against human p53 Lentiviral packaging, stocks production and titration were performed as described previously (59) .
Cell lysis and western blotting
Cells were washed once with phosphate-buffered saline (PBS), harvested, placed on ice and then homogenized in a buffer containing: 20 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) [pH 7.4], 100 mM sodium chloride (NaCl), 100 mM sodium fluoride (NaF), 1% Triton X-100, 1 mM sodium orthovanadate (Na 3 VO 4 ), 5 mM ethylenediaminetetraacetic acid and the COMPLETE TM protease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain). The soluble fraction was obtained by centrifugation at 16 000g for 10 min at 48C. Subsequently, samples were mixed with electrophoresis buffer containing sodium dodecylsulphate (SDS), boiled for 5 min and separated by gel electrophoresis in the presence of SDS on 6 -15% acrylamide -bisacrylamide gels. The proteins were then electrotransferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) or Immobilon-P membranes (Millipore, Bedford, USA), following standard procedures, and the membranes were subsequently blocked with 10% non-fat dried milk in PBS plus 0.2% Tween-20 (PBST). The blocked membranes were incubated overnight with primary antibodies diluted in blocking solution at 48C and the filters were then rinsed at least three times in PBST. After incubating with the corresponding peroxidase-conjugated secondary antibody for 1 h at room temperature, antibody binding was visualized using an enhanced chemiluminiscence detection system (Perkin Elmer Life Science) and quantified using an imaging densitometer (GS-710; BioRad, Hercules, CA, USA) and Quantity One software (BioRad). Densitometry was measured for at least three independent experiments and the values were normalized to those obtained for a control antibody to correct for any variation in the total amount of protein loaded.
The following antibodies were used in western blot: polyclonal antisera against Cleaved Caspase-3 (1:500) and Caspase-3 (1:500; Cell Signaling Technology Inc., Danvers, MA, USA); a polyclonal antiserum against human frataxin (R6.3s, 1:1000) raised against the peptide TLGHPGSLDET-TYERLAEETLC (Protein Tools, Madrid, Spain); a monoclonal antibody against b-actin (1:1000; Sigma) used as a loading control; a polyclonal antiserum against MAP LC-3B (1:1000; Sigma); a monoclonal antibody against a-II-spectrin or a-fodrin (1:1000; Chemicon International Inc., Temecula, CA, USA); polyclonal antisera against human PUMA (1:500; Abcam plc, Cambridge, UK); monoclonal antibodies against p53 (1:1000) and Bax (1:500; BD Pharmingen TM , Bedford, USA); anti-Mouse and anti-Rabbit peroxidaseconjugated antibodies (1:5000; Promega, Madison, WI, USA).
Immunocytochemistry
Immunostaining was performed on cells cultured on coverslips that were fixed at room temperature for 30 min with PBS containing 4% paraformaldehyde. After several washes with PBS, the cells were permeabilized in PBS containing 0.1% Triton X-100 and 1% serum (PBS-TS). The cells were then incubated overnight at 48C with the primary antibody diluted in PBS-TS and after washing with PBS, they were incubated for 1 h at room temperature in PBS-TS with the appropriate Alexa-488-or Alexa-555-conjugated secondary antibody. Following extensive washes, the preparations were stained with DAPI (1:5000; Calbiochem EMD Biosciences Inc.), and after washing, the cells were immediately mounted with Fluoromount-G (Southern Biotech Assoc. Inc., Birmingham, AL, USA). The labelled preparations were examined on an inverted Axiovert 200 (Zeiss) microscope coupled to a CCD camera (Spot ST, Slider).
The following antibodies were used for immunofluorescence: a monoclonal antibody against BrdU (1:100; BD Biosciences, Bedford, USA); a monoclonal antibody against mitochondrial ATP synthase/Complex V (b-subunit, 5 mg/ ml; Molecular Probes, Eugene, OR, USA); a polyclonal antiserum against MAP2A and MAP2B (514, 1:400) (60); a monoclonal antibody against human frataxin (1G2, 1:100; Chemicon International, Inc.); Alexa-488-or Alexa-555-conjugated anti-Mouse and anti-Rabbit antibodies (1:500; Molecular Probes).
Bromodeoxyuridine treatment and staining
Immunostaining was performed on cells growing on coverslips that were treated for 24 h before fixation with BrdU (10 mM; Sigma) diluted in the culture medium. The cells were fixed with PBS containing 4% paraformaldehyde as described above and after several washes with PBS, the cells were permeabilized with PBS supplemented with 0.2% Triton X-100 for 20 min at room temperature. DNA was denatured for later exposure to antibodies by acid treatment with 1 mM HCl prepared in PBS for 10 min. After washing three times with PBS, further denaturation was realized by treating the cells with 2 mM HCl in PBS for 20 min. Following extensive washes, the acid treatment was neutralized with 0.1 M Na 2 B 4 O 7 [pH 8.5] for 2 min at room temperature. After several washes, the cells were blocked with PBS-TS and the immunostaining was carried out as described above. To quantify cell proliferation, at least three randomly selected fields were analysed per coverslip (200 -300 cells/field) in three independent experiments. The rate of proliferation was expressed as the percentage of BrdU-positive cells with respect to the total number of cells, stained with DAPI.
Cell viability
Cell viability was assessed by calcein/acetoxymethyl esterpropidium iodide uptake (61) . Briefly, cells were incubated at 378C for 30 min with 2 mM propidium iodide (Sigma) and 1 mM calcein/acetoxymethyl ester (Molecular Probes). Subsequently, the cells were visualized by fluorescence microscopy using a Zeiss Axiovert 200 inverted microscope and three randomly selected fields were analysed per well (200 -300 cells/field) in at least three independent experiments. Cell death was expressed as the percentage of cells that took up propidium iodide in relation to the total cell number.
Detection of DNA fragmentation: TUNEL staining TUNEL staining was performed with the NeuroTACS TM II In Situ Apoptosis Detection kit (R&D Systems, Germany), using biotinylated nucleotides according to manufacturer's instructions. Briefly, cells were cultured on coverslips and then fixed with 4% paraformaldehyde. The cells were then treated with NeuroPore TM for 30 min at room temperature and permeabilized with Proteinase K for 30 min at 378C. After several washes with DNase-free water, the cells were incubated at room temperature with a peroxidase quenching solution and labelling buffer for 5 min each. Subsequently, the cells were labelled for 1 h at 378C, and the coverslips were then incubated with streptavidin-horseradish peroxidase solution and developed with 3,3 ′ -diaminobenzidine. Finally, the cells were washed thoroughly with PBS and mounted on glass slides with Fluoromount-G. The cells were visualized on a Zeiss Axiovert 200 inverted microscope coupled to a CCD camera (Spot ST, Slider). To analyse cell death, three fields per coverslip (200 -300 cells/field) from three independent experiments were selected randomly. Cell death was expressed as the percentage of labelled cells compared with the total cell number.
Acridine orange staining
The accumulation of acridine orange within the acidic vesicles of cells has been used as an indicator of increased autophagic activity (27, 62) . Cells were incubated at 378C in the presence of 1 mM acridine orange (Sigma) for 30 min, after which they were tripsinized and centrifuged at 90g for 5 min. The pellet containing the cells was then washed in PBS, centrifuged again under the same conditions, and the cells were resuspended in PBS and analysed in a FACScalibur flow cytometer. The results were examined with the Cell Quest programme and they were presented as the increase in fluorescence intensity measured in FL2 from at least three different experiments.
ROS measurement
The presence of superoxide anion inside the mitochondria was measured with the probe MitoSOX TM Red by flow cytometry as described previously (63) . The cells were incubated for 45 min at 378C with 5 mM MitoSOX TM Red (Molecular Probes). After this incubation, the cells were tripsinized and centrifuged at 90g for 5 min. The pellet containing the cells was then washed in PBS and centrifuged again under the same conditions. Finally, the cells were resuspended in buffer MIB (mitochondria incubation buffer) (64) containing 68 mM sucrose, 10 mM HEPES [pH 7.4], 70 mM KCl and 1 mM ethylene glycol-bis(2-aminoethylether)-N, N, N ′ , N ′ -tetraacetic acid. The cell suspension was analysed in a FACScalibur flow cytometer. The results were examined using the Cell Quest programme and they were presented as the increase in fluorescence intensity measured in FL2, from at least three different experiments. The results were normalized using shRNA sc as the reference.
Statistical analysis and data processing
The mean + SEM values of at least three independent experiments are represented in the figures. Statistical comparison of the data sets was performed using Student's t-test. The differences are presented with their corresponding statistical significance or P-value, which is the probability that the observation in a sample occurred merely by chance under the null hypothesis.
